v3.25.2
FAIR VALUE MEASUREMENTS - Additional Information (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2023
USD ($)
Jul. 01, 2015
Restructuring Cost and Reserve [Line Items]              
Asset impairment charges $ 24,000,000 $ 0 $ 24,000,000 $ 0      
Fair value of debt 5,600,000,000   5,600,000,000   $ 6,100,000,000    
UMass Joint Venture              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Ownership percentage by noncontrolling owners             18.90%
Invigorate Program              
Restructuring Cost and Reserve [Line Items]              
Asset impairment charges 24,000,000   24,000,000        
Fair Value, Inputs, Level 3 | Contingent Consideration              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Total fair value adjustments included in earnings - realized/unrealized     6,000,000        
Liability 112,000,000   112,000,000   106,000,000    
Fair Value, Inputs, Level 3 | Contingent Consideration | Other Liabilities              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Liability 84,000,000   84,000,000   101,000,000    
Fair Value, Inputs, Level 3 | Contingent Consideration | Accounts Payable and Accrued Expenses              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Liability $ 28,000,000   $ 28,000,000   $ 5,000,000    
Haystack Oncology, Inc. | Comparable Company Revenue Volatility              
Business Combination [Line Items]              
Measurement input 0.35   0.35        
Haystack Oncology, Inc. | Discount rate              
Business Combination [Line Items]              
Measurement input 0.105   0.105        
Haystack Oncology, Inc. | Additional, Based on Revenue              
Business Combination [Line Items]              
Maximum contingent consideration payment           $ 100,000,000  
Haystack Oncology, Inc. | Additional, Reimbursement Coverage              
Business Combination [Line Items]              
Maximum contingent consideration payment           $ 50,000,000  
Haystack Oncology, Inc. | Additional Impact | Discount rate              
Business Combination [Line Items]              
Measurement input 0.05   0.05        
Haystack Oncology, Inc. | Changing Comparable Company Revenue Volatility | Comparable Company Revenue Volatility              
Business Combination [Line Items]              
Measurement input 0.25   0.25        
Increase in contingent consideration liability     $ 4,000,000        
Haystack Oncology, Inc. | Changing Discount Rate | Discount rate              
Business Combination [Line Items]              
Measurement input 0.070   0.070        
Increase in contingent consideration liability     $ 2,000,000